Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;14(8):2922-2927.
doi: 10.21037/tlcr-2025-564. Epub 2025 Aug 22.

Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer

Masahiro Morise  1 , Ichidai Tanaka  1 , Makoto Ishii  1
Affiliations
Editorial

Long-term survival outcomes of lorlatinib in advanced anaplastic lymphoma kinase (ALK)-fusion positive non-small cell lung cancer

Masahiro Morise et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Anaplastic lymphoma kinase (ALK); alectinib; brain metastasis; brigatinib; lorlatinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-564/coif). M.M. reports lecture fees from Taiho, Boehringer-ingelheim, Daiichi Sankyo, Eli Lilly, Chugai, Astra Zeneca, Ono, Pfizer, and MSD; other (principal investigator of pharmaceutical companies initiated trial) from Chugai, Astra Zeneca, Ono, Pfizer, Merk Serono, Kissei, Taiho, and Novartis; and research grants from Boehringer-ingelheim, and Eli Lilly, outside the submitted work. I.T. received research funding from Chugai Pharmaceutical Co.; and reports consulting/advisory roles: AstraZeneca; honoraria: AstraZeneca, Chugai Pharmaceuticals, Bristol-Myers Squibb, MSD K.K, Novartis Pharma K.K., Takeda Pharmaceuticals, Ono Pharmaceutical Co. and Daiichi Sankyo Company. The other author has no conflicts of interest to declare.

Comment on

References

    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. 10.1038/nature05945 - DOI - PubMed
    1. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77. 10.1056/NEJMoa1408440 - DOI - PubMed
    1. Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 2017;390:29-39. 10.1016/S0140-6736(17)30565-2 - DOI - PubMed
    1. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2017;377:829-38. 10.1056/NEJMoa1704795 - DOI - PubMed
    1. Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med 2019;7:437-46. 10.1016/S2213-2600(19)30053-0 - DOI - PubMed

LinkOut - more resources